← All trials
NCT01710007
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Sep 1, 2012
- Completion date
- Nov 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Orient Pharma Co., Ltd.Lead sponsor
- Cardinal Tien HospitalOverall official - principal investigator
- Taichung Veterans General HospitalOverall official - principal investigator
- Government of TaiwanOverall official - principal investigator
- Cheng-Hsin General HospitalOverall official - principal investigator
- Taipei Medical UniversityOverall official - principal investigator
- Tzu Chi UniversityOverall official - principal investigator
- Orient Europharma Co., Ltd.Collaborator
- Taipei Veteran General hospitalOverall official - principal investigator
- Chang Gung UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.